Fluticasone Furoate (FF) A Novel Inhaled Corticosteroid (ICS) Demonstrates Prolonged Lung Absorption Kinetics In Man

Fluticasone furoate/fluticasone propionate - different drugs with different properties

“…The ester group also contributes to the physicochemical characteristics of the molecule which impact on solubility, dissolution rate, tissue affinity, and hence pharmacokinetic and pharmacodynamic properties. Thus, the ester derived from 2-furoic acid in FF confers higher affinity for both nasal and lung tissue compared with FP ( 5 , 6 ) and recent studies with inhaled FF have shown that this translates to enhanced lung residency and once-daily efficacy in asthma ( 7 , 8 ). There is already some evidence that the characteristics of FF may result in superior symptom reduction compared with FP ( 9 , 10 ) or similar improvements in symptoms at less frequent dosing schedules (11) , which could result in reduced health-care costs/concomitant medication use (12) ; however, prospective, randomised, head-to-head studies are required to provide a definitive answer.…”

Reply

“…As the study compound, FF, was still at a very early stage of development, the purpose of the study was to assess the duration of effect of 1000 μg FF against placebo by showing a protective effect of a single dose of FF against AMP hyperresponsiveness that lasted up to 26 h. As expected, when we compared FP vs placebo at 26 h, the results were statistically non‐significant providing only indirect evidence of a longer duration of effect for FF. Subsequent to our study, trials have now been conducted that more formally demonstrate a duration of effect for FF up to 24 h (2, 3). Taken together, these results suggest that FF may be suitable for once‐daily dosing in asthma.…”